Radical treatment of limb soft-tissue sarcomas is typically combination treatment of surgery and radiotherapy. The aim of radical treatment is to achieve excellent local control rates with minimal treatment-related morbidity and adverse effects on the quality of life. This article looks at the use and timing of radiotherapy and associated complications. The arguments for and against neoadjuvant, intraoperative, adjuvant or no radiotherapy will be discussed.
The major therapeutic goals when treating extremity STS are patient survival, local tumour control, maximising limb function and minimising morbidity from treatment. Treatment-related morbidity can cause considerable physical and psychological disability resulting in reduced quality of life. New treatment paradigms for sarcoma should concentrate not only on local control and survival but also on the consequences of the treatment itself.
Neoadjuvant (Preoperative) Radiotherapy
Historically neoadjuvant radiotherapy has been used in extremity STSs where upfront limb-conserving surgery is considered difficult.
if shrinkage of the sarcoma could facilitate conservative surgery then radiotherapy may be tried. This approach requires extensive collaboration between radiologists, surgeons and radiotherapists.
it is generally accepted if a sarcoma is truly unresectable without an amputation then neoadjuvant treatment, either radiotherapy or chemotherapy, is unlikely to render the tumour operable.
Over the last 15 years, neoadjuvant radiotherapy has become the standard of care in several countries, particularly canada. Trials have shown equivalent local control and survival rates to adjuvant radiotherapy. 3 The toxicity profiles are different, with increased acute wound complications with neoadjuvant radiotherapy and increased late toxicities with adjuvant radiotherapy (see section below).
Traditional Response Evaluation criteria in Solid Tumors (REciST) criteria for neoadjuvant radiotherapy in STSs are not reliable predictors of pathological response. Myxoid liposarcomas are extremely radiosensitive tumours that frequently show 100 % necrosis after neoadjuvant radiotherapy. 4 Traditional REciST radiological reporting in these cases usually report stable disease or no response to treatment. This is clearly not the case, and radiologists who are experienced in sarcoma radiology and the radiological changes in response to treatment are crucial in the discussion of these patients' management. Surgery is usually planned for four to six weeks postneoadjuvant radio therapy to allow for any cytoreduction to occur, but before late toxicities such as fibrosis and oedema that could make surgery more difficult.
Adjuvant (Postoperative) Radiotherapy
Potter et al. 6 first reported that limb-preserving surgery with radiotherapy had equivalent local control results to amputation in extremity STS 
Arguments for Preoperative or Postoperative Radiotherapy
the theoretical radiobiological arguments in favour of neoadjuvant or adjuvant radiotherapy can be seen in Table 1 tended to be less extensive rather than more.
the French Sarcoma group found a fourfold difference in local recurrence rate between r0 and r1 resections. 12 larger tumours have been shown to have an increased likelihood of r1 resection. 13 Inadequate resections have been demonstrated to show a doubled risk of local recurrence, but local recurrence and metastatic disease have not been shown to have a causal relationship.
In a series from the mayo clinic, treated by surgery alone, there was a five-year local recurrence rate of 20 %. this was however with a mixed population and only five deep, high-grade tumours. the recurrence rate 
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Wound Complications
the major surgical concern of preoperative radiotherapy is wound complications. these have been shown to be higher in the proximal lower extremity than at other sites. a series of 317 patients from the university of Florida revealed a 50 % wound complication rate in StSs resected from the medial thigh. 18 Wound complications occurred in 44 % of patients treated by induction radiotherapy in melbourne, australia. the rate was similar whether the wounds had been closed primarily, by skin grafting or by a flap. there was an increased risk of complications in patients over 40 years of age. 19 Surgery was, however, carried out less than three weeks from completion of radiotherapy.
Imaging reveals an incidence rate of seroma of 7.7 % (2/26) for surgery alone and 76 % of surgery with radiotherapy. 20 treatment-related osteoporosis occurred in 19 % and 28 % of the treatment groups, respectively. twelve patients developed lower limb osteoporosis: five were in the surgery alone group and six in the surgery and radiotherapy group of which there were one and five pathological fractures, respectively.
Pathological Fractures
post-irradiation pathological fractures can be difficult to manage and troublesome to heal. Incidence varies from 2 % to 10 %. 18, 21, 22 In the largest series from toronto, the major risk factors were for females, over 50 years of age and pertained to the proximal femur. maintainance of a mean bone dose of less than 37 gy reduced the risk of fracture. 21 the volume of bone irradiated is an important risk factor in determining risk of radiation-induced fracture. Extensive periosteal stripping, particularly of the proximal femur, should alert the surgeon to the risks of radiationinduced fracture and prophylactic fixation should be considered. While pathological fracture can occur, even after prophylactic stabilisation, they often do not require additional surgical management. In the uK, many sarcoma specialist centres are recruiting to the VortEX study. this is a national cancer research network (ncrn)-run rct looking at adjuvant radiotherapy. In the experimental arm, smaller treatment fields are used on the basis that the majority of sarcoma recurrences occur within 2 cm from the original tumour. the investigators are hoping that the traditional very large radiation fields may no longer be needed and that toxicity may be reduced while still maintaining excellent local control rates. larger field sizes are known to correlate with an increased incidence of fibrosis and joint stiffness.
While centres are recruiting to this study the widespread introduction of neoadjuvant radiotherapy is unlikely to occur.
For each individual sarcoma patient, the multidisciplinary team should discuss and agree local therapy (both primary and adjuvant therapy)
prior to surgery to optimise outcomes. consideration should be given to the functional deficits and complications expected from all modalities used for local control. available evidence suggests that only patients with small, low-grade tumours under the age of 50 years should be spared radiotherapy. this age has not been ratified in large studies. n
